A5009303158- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Esophageal and GI Pathology
- HER2/EGFR in Cancer Research
- Intraperitoneal and Appendiceal Malignancies
- Monoclonal and Polyclonal Antibodies Research
- Immune cells in cancer
- Cancer survivorship and care
- Hepatocellular Carcinoma Treatment and Prognosis
- Multiple and Secondary Primary Cancers
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
City of Hope
2016-2025
Amgen (United States)
2023-2025
City Of Hope National Medical Center
2015-2024
Therapeutics Clinical Research
2019-2022
Translational Genomics Research Institute
2021
Soochow University
2021
Second Affiliated Hospital of Soochow University
2021
University of Arizona
2016-2018
Beckman Research Institute
2012-2017
Angeles Clinic and Research Institute
2012-2017
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% gastric cancers are adenocarcinomas, which typically classified based on anatomic location and histologic type. generally carries a poor prognosis because it often diagnosed at an advanced stage. Systemic therapy can provide palliation, improved survival, enhanced quality life in patients with locally or metastatic disease. The implementation biomarker testing, especially analysis HER2 status,...
Abstract Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma most common histology in Eastern Europe and Asia, adenocarcinoma North America Western Europe. Surgery a major component treatment locally advanced resectable esophageal esophagogastric junction (EGJ) cancer, randomized trials have shown that addition preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including...
Gastric cancer is the fifth most frequently diagnosed and third leading cause of death from in world. Several advances have been made staging procedures, imaging techniques, treatment approaches. The NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) for Cancer provide an evidence- consensus-based approach management patients with gastric cancer. This manuscript discusses recommendations outlined staging, assessment HER2 overexpression, systemic therapy locally advanced or...
<h3>Importance</h3> Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. <h3>Objective</h3> To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with G/GEJ programmed cell death ligand 1 (PD-L1) combined positive score (CPS) greater. <h3>Design, Setting, Participants</h3> The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional...
Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated high disease control rate and favorable progression-free survival (PFS); however, reported rates pembrolizumab nivolumab are variable often <50%, suggesting that additional predictive biomarkers needed.
Esophageal cancer is the sixth most common cause of deaths worldwide. Adenocarcinoma more in North America and Western European countries, originating mostly lower third esophagus, which often involves esophagogastric junction (EGJ). Recent randomized trials have shown that addition preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival patients with resectable cancer. Targeted therapies trastuzumab ramucirumab produced encouraging results...
<h3>Importance</h3> Although geriatric assessment–driven intervention improves patient-centered outcomes, its influence on chemotherapy-related toxic effects remains unknown. <h3>Objective</h3> To assess whether specific (GAIN) can reduce in older adults with cancer. <h3>Design, Setting, and Participants</h3> A randomized clinical trial enrolled 613 participants from a National Cancer Institute–designated cancer center between 2015 2019. Patients were 65 years solid malignant neoplasm,...
Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors.
LBA4007 Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined positive score ≥1 (CPS ≥1), HER2-negative, advanced GC. Methods: Eligible were randomized 1:1:1 to 200 mg Q3W for up 2 y, (cisplatin 80 mg/m + 5-FU 800 /d on d1-d5 [or capecitabine 1000 BID d1-d14 per local guideline]) placebo C. Randomization stratified by region, disease status, and fluoropyrimidine treatment. Primary endpoints OS CPS ≥10 PFS (RECIST v1.1;...
G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy KRAS inhibitors has yielded only modest efficacy. Combining the inhibitor sotorasib panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be effective strategy.
Several post hoc analyses of randomized controlled trials (RCTs) suggested the importance microsatellite instability (MSI) as a positive predictive factor to immunotherapy in patients with advanced gastric cancer (GC); however, individually these have low statistical power.RCTs investigating treatment or without an anti-programmed cell death protein 1 (PD-1) agent for GC and providing outcome according MSI status were selected. The hazard ratio (HR) odds used compare effect on survival...
Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of shows primary resistance or short-term disease control. Since malignant effusions represent an immune-suppressed niche, we investigated whether peritoneal involvement without ascites is poor prognostic factor dMMR/MSI-H metastatic colorectal cancer (mCRC) and gastric (mGC)...
Nanoparticle-based therapeutics are being used to treat patients with solid tumors. Whereas nanoparticles have been shown preferentially accumulate in tumors of animal models, there is little evidence prove that intact localize humans when systemically administered. Here, tumor and adjacent, nonneoplastic tissue biopsies obtained through endoscopic capture from gastric, gastroesophageal, or esophageal cancer who administered the nanoparticle CRLX101. Both pre- postdosing samples adjacent...
Nanoparticles are currently being investigated in a number of human clinical trials. As information on how nanoparticles function humans is difficult to obtain, animal studies that can be correlative behavior needed provide guidance for Here, we report animals and CRLX101, 20- 30-nm-diameter, multifunctional, polymeric nanoparticle containing camptothecin (CPT). CRLX101 phase 2 trials, data from several the investigations compared with results multispecies studies. The pharmacokinetics...
12010 Background: Geriatric assessment (GA) can predict chemotherapy (chemo) toxicity in older adults (age ≥65) with cancer. However, evidence regarding the effect of GA-driven intervention (GAIN) on incidence chemo has been limited. Therefore, we conducted a randomized controlled trial evaluating impact GAIN vs. standard care (SOC) Methods: Patients (pts) age ≥65, diagnosed solid malignancy, and starting new regimen at City Hope were eligible (NCT02517034). In 2:1 ratio, 600 pts randomly...
Alterations in the DNA damage response (DDR) pathway confer sensitivity to certain chemotherapies, radiation, and other repair targeted therapies. BRCA1/2 are most well-studied DDR genes, but recurrent alterations described members across cancers. Deleterious may sensitize tumor cells poly (ADP-ribose) polymerase inhibition, there also increasing data suggesting that be synergy with immune checkpoint inhibitors. The relevance of defects gastrointestinal (GI) cancers is understudied. We...
Abstract Purpose: Pembrolizumab demonstrated efficacy in PD-L1–positive [combined positive score (CPS) ≥1] advanced gastric/gastroesophageal junction (G/GEJ) cancer the first-, second-, and third-line setting KEYNOTE-062, KEYNOTE-061, KEYNOTE-059, respectively. To better delineate specificity of CPS as a predictor clinical outcomes, we analyzed pembrolizumab patients with ≥ 10 these trials. Patients Methods: Included were tumors from KEYNOTE-059 cohort 1 (pembrolizumab, n = 46; post hoc),...
Abstract Purpose: This prespecified exploratory analysis evaluated the association between tumor mutational burden (TMB) status and outcomes of first-line pembrolizumab±chemotherapy versus chemotherapy in KEYNOTE-062. Patients Methods: In patients with advanced gastric cancer evaluable TMB data, we (continuous variable; square root scale) assessed FoundationOne CDx clinical [objective response rate (ORR), progression-free survival (PFS), overall (OS)] using logistic (ORR) Cox proportional...